Better hydroxyurea dosing for sickle cell patients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial checks whether monitoring hydroxyurea drug levels in the blood can help doctors find the best dose for sickle cell patients. It focuses on people with HbSS who have recently had a pain crisis or whose current dose isn't working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have sickle cell disease type HbSS.
- You are between 2 and 35 years old.
- You have been in the hospital for a pain crisis in the last 3 months, or your current hydroxyurea dose isn't working well (less than 30 mg/kg).
- You can take hydroxyurea (no severe liver or kidney problems, and no allergy to the drug).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use highly effective birth control during the study and for 6 months after.
- You cannot have had a blood transfusion or erythropoietin in the last 3 months, and you cannot have very low blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors personalize hydroxyurea treatment for people with sickle cell disease of Nigerian descent by looking at how your body processes the medication. The goal is to find the dose that works best for you with fewer side effects.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.